Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

3 in the second quarter of 2008, compared to $109,153 in the second quarter of 2007. General and administrative expenses were $542,043, down from $988,233 in the second quarter of 2007.

Operating income was $2.8 million in the second quarter of 2008 compared to $3.6 million in the second quarter of 2007.

Net income for the second quarter of 2008 was $2.2 million, or $0.05 per diluted share, compared to $3.0 million, or $0.07 per fully diluted share, in the second quarter of 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $2.5 million, or $0.06 per fully diluted share, in the second quarter of 2008, compared to adjusted net income of $3.4 million, or $0.08 per fully diluted share, in the second quarter of 2007.

Six Month Financial Results

Revenues for the first six months of 2008 were $31.1 million, up 47.4% from revenues of $21.1 million in the first six months of 2007. Gross profit was $13.6 million, up 67.8% from gross profit of $8.1 million for the six months of 2007. Gross margin was 43.8%, compared to 38.5% for the first six months of 2007. Operating income was $4.3 million, compared to $4.8 million for the first six months of fiscal 2007.

Net income was $3.2 million, or $0.07 per fully diluted share, compared to $3.9 million, or $0.09 per fully diluted share, for the first six months of fiscal 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $3.9 million, or $0.08 per fully diluted share, for the first six months of 2008, compared to adjusted net income of $4.4 million, or $0.10 per fully diluted share, for the first six months of 2007.

Financial Condition

As of June 30, 2008, Lotus had $3.4 million in cash and equivalents, and $27.0 million of working capital. Total assets were $49.0 million comp
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
(Date:9/20/2014)... 2014 MediVet America and ... groundbreaking surgery at the specialized Wolvega Horse Clinic. , ... flexor tendon was ruptured 90% and her deep digital ... a death sentence for a horse. , The clinic ... treatments . This revolutionary regenerative option for ruptured ...
(Date:9/19/2014)... -- InterMune, Inc. (Nasdaq: ITMN ) today announced ... settle the litigation in the Delaware Court of Chancery ... as of August 22, 2014, among Roche Holdings, Inc., ... of the Memorandum of Understanding, the Company agreed to ... exhibit reflecting the amendment to the Company,s Schedule 14D-9 ...
(Date:9/19/2014)... rarely simple. From crop yields to disease risks, the ... considered "complex traits." Just as for heightthe textbook example ... human disease are shaped by multiple genetic and environmental ... To track down such genes, geneticists typically mate two ... mouse and a small mouseand then study their descendents, ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19Want to link genes to complex traits? Start with more diversity 2
... Sweden has shown that biosynthetic corneas can help regenerate and ... results, from an early phase clinical trial with 10 patients, ... Science Translational Medicine . "This study is important because ... cornea can integrate with the human eye and stimulate regeneration," ...
... Enterprise Institute (Mtech) Bioprocess Scale-Up Facility (BSF) will double ... equipment, and create a pilot plant for biofuels in College ... from the Maryland Biotechnology Center . "The ... make sure the BSF,s capabilities are available to the growing ...
... bioserie is first to market with a line ... device owners the protection they demand while using only ... use of the latest in bioplastics technology offers considerably ... of environmental toxic pollution once the cover is discarded. ...
Cached Biology Technology:Seeing the world with new eyes: Biosynthetic corneas restore vision in humans 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 3bioserie Introduces the World's First 'Made of Plants' iPhone 4 Cover 2
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... resource unveiled today by researchers from several Harvard ... provides both experienced and aspiring researchers with the ... operate robots made from soft, flexible materials. , ... cutters, and other advances in manufacturing technology, soft ... Using principles drawn from conventional rigid robot design, ...
(Date:9/19/2014)... study the unique bioelectric signaling system of the electric ... The OU researcher is working to understand how ... signals used to map the world around them. ... 500-600 discharges a second throughout their lives. The ... but necessary for survival. , "There is evidence that ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... painted with gold purify the air when they are ... of Technology experts have discovered. Associate Professor Zhu ... Sciences said that glaziers in medieval forges were the ... different sizes. Professor Zhu said numerous church ...
... detailed images of the body,s anatomy. Thanks to novel ... scientist Eric Ahrens, MRI can be used to visualize ... in the living body. The ability to non-invasively locate ... aid the study and treatment of cancer, inflammation, and ...
... August 20, 2008 New phase 2 data published ... investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic ... PTC124 results in statistically significant improvements in the chloride ... study was conducted at the Hadassah Hebrew University Hospital ...
Cached Biology News:Air-purifying church windows early nanotechnology 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
... Rabbit Antibody to CRF ... with the ovine CRF sequence ... Cells and fibres are found ... of rat brain in colchicine ...
... fully genetically encoded fluorescent sensor capable for ... (H2O2), one of the main ROS generated ... yellow fluorescent protein inserted into the regulatory ... HyPer demonstrates submicromolar affinity to H2O2 and ...
...
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide....
Biology Products: